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OBJECTIVES: There are three main parts during a product’s lifecycle when satisfac-
tion instruments are particularly useful. These are to aid: 1) getting the product to the 
market; 2) getting the market to the product; and 3) demonstrating value for health 
care practitioners during daily clinical practice. This study investigates whether the 
development and implementation of treatment satisfaction instruments during a prod-
uct’s lifecycle are informed by their purpose. METHODS: A literature review was 
performed between 2000 and 2010 using electronic databases (PUBMED, PsycINFO, 
and EMBASE) and keywords such as “satisfaction” and “medication” or “drug” and 
“questionnaire.” Relevant articles were reviewed in detail to extract information 
regarding the satisfaction instrument used, its development and validation, and when 
the instrument was used during a product’s lifecycle. Additional information was 
collated including the type of studies the instruments were used in, clinical condition/
indication, type of data generated (e.g. descriptive), and whether satisfaction was 
associated with other endpoints. RESULTS: Of 875 abstracts, 105 articles were 
further considered. The review indicated similarities regarding the development and 
validation of satisfaction instruments, such as using patient input to derive the items 
and exploring classical measurement properties speciﬁ c to the target population. 
However, the speciﬁ cities of the implementation of treatment satisfaction during the 
three main stages of a product’s lifecycle were rarely considered. CONCLUSIONS: 
The development and implementation of treatment satisfaction instruments during a 
product’s lifecycle rarely consider the purpose. By “keeping the end in mind,” data 
from treatment satisfaction instruments can help three key parts: 1) getting the product 
to the market thus helping to generate evidence as part of an overall value proposition; 
2) getting the market to the product; and 3) demonstrating the value to clinical prac-
tice. Furthermore, the development, validation and interpretation of scores from 
treatment satisfaction instruments should be sensitive to the intended purpose. 
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OBJECTIVES: To collect information serve as a background for further activities of 
the eBayesMet project. To perform assessment of the frequency of use the particular 
statistical methods for meta-analyses and indirect comparisons in existing systematic 
reviews and HTA reports. METHODS: Database of Reviews of Effectiveness (DARE) 
was searched for relevant reviews published between January 2009 and March 2010. 
RESULTS: The majority of meta-analyses were prepared by using direct statistical 
methods (97%). The most popular expression about ﬁ xed model was that ﬁ xed effect 
model with the Mantel-Haenszel was used (36%). In case of random model, informa-
tion that method DerSimonian Laird was selected (38%) was used most often. Meta-
analyses were prepared mostly based on randomized controlled trials (87%) and in 
3% only on observational studies. In meta-analyses based on RCTs in 42% of cases 
authors mentioned that to make strong conclusion more studies were needed. Employ-
ing Bayesian methods was generally very rare. For indirect comparisons six methods 
were recognized and the most common type was MTC Bayesian Model (53%). 
Observational studies were not included in any identiﬁ ed analysis. In 40% of the 
review information indicating the need for additional studies was contained. CON-
CLUSIONS: Our systematic reviews demonstrates a wide range of approaches and 
methods for conducting meta-analyses and indirect comparison used in current prac-
tice. The most popular approach for indirect comparison is Bayesian included network 
and MTC (over 65%). However performed analysis indicated that Bayesian approach 
is still marginal methods for performing direct comparison based on head to head 
studies. Bayesian models have essential advantage: some additional data can be 
included (as a prior distribution). This extra information can be for instance data from 
observational studies. However it should be emphasized, that in the analyzed random 
sample of systematic reviews studies other than RCT were included in only 13%.
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ECONOMIC EVALUATIONS
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OBJECTIVES: Estimates of mean cost and quality-adjusted-life-years are central to 
the cost-effectiveness analysis of health technologies. They are often calculated from 
curve ﬁ ts to overall survival and time on treatment, ideally by the method of maximum 
likelihood applied to individual patient data. However, such data is often not avail-
able. Instead, curves are commonly ﬁ t to summary Kaplan-Meier estimators, either 
by regression of the transformed estimator or by minimizing the sums of squares of 
differences between actual and ﬁ tted values. However, the tail of the estimator is often 
uncertain due to small numbers of patients at risk, and the curve ﬁ ts do not yield 
estimates of the true uncertainty in survival times, which is a very important compo-
nent of overall uncertainty in cost-effectiveness. Here, I describe a new, more accurate 
method of ﬁ tting survival curves to summary survival data. METHODS: First, I 
estimate the underlying individual patient data from the Kaplan-Meier estimator, 
numbers of patients at risk and from other published trial-related information. The 
ﬁ tted curve is then estimated by maximum likelihood given the estimated underlying 
individual patient data. RESULTS: Simulation applied to individual patient data 
shows that the method tends to give a more accurate curve ﬁ t than the traditional 
methods of ﬁ tting to the Kaplan-Meier estimator. Furthermore, the curve ﬁ t is often 
very similar to that derived by ﬁ tting to the underlying individual patient data by 
maximum likelihood. The method naturally yields accurate estimates of the uncer-
tainty in survival times. When applied to economic evaluations submitted to NICE, 
the method often yields substantially improved estimates of cost-effectiveness com-
pared to estimates based on ﬁ tting survival curves in the traditional manner. This 
highlights the sensitivity of many cost-effectiveness analyses to curve ﬁ ts. CONCLU-
SIONS: When only summary survival data is available, I recommend the method for 
cost-effectiveness analysis.
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CONFOUNDERS IN OBSERVATIONAL STUDIES
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OBJECTIVES: Outcomes research often employs observational designs (e.g., disease 
registries, administrative health care data sets, chart reviews). Researchers using obser-
vational data may ﬁ nd various amounts of missing data for confounders when analyz-
ing the association between an exposure (such as treatment use) and an outcome (such 
as an adverse event). This abstract examines the case when a potentially important 
confounding variable has a large amount of missing data and compares the analytic 
methods that may be used in this situation. METHODS: Strategies for handling 
missing confounder information include: (1) ignore confounders with lots of missing 
values; (2) exclude cases that are missing a confounder value; (3) impute a value for 
the confounder; (4) include missing as a separate category in the analysis. Data from 
a disease registry were used as the basis for simulations to compare the odds ratio for 
risk of death in patients who received a treatment compared to those without treat-
ment. Both a clinical measurement and a subjective physician assessment are known 
to confound the relationship between treatment and death. RESULTS: The most 
problematic pattern of missing data was informative missing data. In one simulation, 
the clinical measurement was a strong predictor of death; however, it was dispropor-
tionately missing in patients who had died. The physician assessment predicted death 
strongly among patients missing the clinical measurement, but only weakly in patients 
not missing the clinical data. Different approaches to the missing confounder data 
either exacerbated or ameliorated the problem. CONCLUSIONS: Excluding cases can 
create misleading results due to selection bias. Combining all missing values into a 
separate category can create data “noise” (i.e., classiﬁ cation error); however, this may 
be the most transparent strategy and least likely to bias results. It is important to 
include all cases and all potential confounders in the analysis of outcomes research 
studies.
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OBJECTIVES: To collect information serve as a background for further activities of 
the eBayesMet project. To identify statistical methods and approaches for performing 
meta-analyses and indirect comparisons. To describe limitations and mathematical 
background, to discuss advantages and disadvantages of identiﬁ ed methods. 
METHODS: Databases such as MathSciNet, Medline and Cochrane Methodology 
Group resources, textbooks, guidelines for preparing systematic reviews were 
searched. We focused on papers with strictly mathematical descriptions of presented 
methods. RESULTS: Eleven main statistical methods were identiﬁ ed. There were six 
methods of meta-analysis (Inverse Variance, Mantel-Haenszel, DerSimonian-Laird, 
Peto, Bayesian and Generalized Linear Mixed Models for direct comparison), and ﬁ ve 
methods of indirect and mixed comparison (Bûcher, Minimal Squares, Lumley, Bayes-
ian Mixed Treatment Comparison and Generalized Linear Mixed Models for indirect 
comparison). Moreover, there are different variants of some of these methods. For 
any type of analysis (direct, indirect, network, ﬁ xed, random, etc.) and any given data, 
there is an adequate version of Bayesian method for performing estimation. We found 
the Bayesian approach to be generally the most ﬂ exible.Analysis of precision and 
credibility of all identiﬁ ed statistical methods of meta-analysis and indirect comparison 
will be prepared in the next part of eBayesMet project. CONCLUSIONS: There are 
several statistical methods for performing proper data analysis in any model. The 
problem is with choosing optimal one for the given data set. On the other hand, all 
methods are less reliable and accurate for samples of data, especially for small (or 
zero) number of events in one or both arms. There is variety of statistical methods 
combining direct and indirect evidence, from which the most ﬂ exible is Mixed 
